DexCom's key Q3 earnings factors include Stelo sales, updates on sales channels, and potential share buybacks. See why I ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A ...

DexCom's newest G7 CGM competes closely with Abbott's FreeStyle Libre 3, both products have very similar features and design innovations. DexCom's forward multiples suggest the company is trading ...

But even if we aren't in a bear market, buying shares of beaten-down stocks that have what it takes to recover is also an ...

A top healthcare stock to own over the years has been DexCom (NASDAQ: DXCM). The company makes continuous glucose monitors ...

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an ...

Today, DexCom is the leading CGM company, with an estimated 40% market share. Importantly, CGM products are relatively nascent. DexCom generates nearly $4 billion in annual sales on a user base of ...

The International Longshoremen’s Association strike is a test of whether unions can push back against a wave of automation ...

DexCom has helped revolutionize diabetes care with continuous glucose monitoring (CGM) devices. Patients wear a patch that continuously transmits blood sugar data to a device or smartphone.